IL21 and type 1 diabetes mellitus: Although trials of several anti–IL-21 monoclonal antibodies for autoimmune diseases have been conducted (19, 53–55), the only completed phase II trial is of treatment combined with liraglutide in patients newly diagnosed with T1D (ClinicalTrials.gov NCT02443155).